Drug intelligence / Profile preview

LY3848575

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LY3848575 is a monoclonal antibody developed by Eli Lilly for the treatment of neuropathic pain, specifically chronic neuropathic pain associated with distal sensory polyneuropathy. It acts as an inhibitor of epiregulin (EREG), a member of the epidermal growth factor family implicated in nerve injury and pain signaling pathways. The drug is currently in Phase 2 clinical trials to evaluate its safety and efficacy compared to placebo in patients with painful distal sensory polyneuropathy. Administration routes under investigation include intravenous and subcutaneous injection[2][3][9].

Other names: Epiregulin mAb

Targets

EREG (Epiregulin)

Beyond the preview

Go deeper on LY3848575.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3848575.

Explore the full profile